Effects of puerarin on GSK-3 in hepatic cell in rats with insulin resistance

Abstract

Abstract: AIM:To develop a rat model of insulin resistance and observe the effect of puerarin injection on expression of GSK-3 in insulin resistance rats . METHEDS:30 Wistar rats were divided into three groups randomly :control group, model group and puerar- in group .The model group and puerarin group were given high fat diet ( 20 %surcose, 10 %ard, 2 .5 %chlesterol, 1 % cholic acid) for 4 weeks .Then the puerarin group was given abdominal injection puerarin 100 mg·kg ^-1·d^-1 for six weeks .At the end of this experiment, we detect GSK-3 protein by western-blot analysis .Then computer image pattern analysis system was used to analyze the ex- pression of GSK-3 in the hepatacyte.RESULTS:Tthe model group showed a hyperglycemia, hyperinsulinism, the ISI decreased and HOMA-IR increased .GSK-3 ex- pression enhanced in the model group, but the expression of GSK-3 in puerarin group decreased compared to the model group .CONCLUSION:Puerarin injection can significantly decreased the expression of GSK-3 and im- prove insulin resistance .

Key words: puerarin , insulin resistance , GSK-3 , ani- mal model , liver

CLC Number:

R979 .15

HONG Tian, BI Hui-min, BI Xin. Effects of puerarin on GSK-3 in hepatic cell in rats with insulin resistance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(2): 207-210.

References 14

1	Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR,Mills GB . Phos- phorylation and inactivation of glycogen synthase kinase 3 by protein kinase A[ J] . Proc Natl Acad Sci USA, 2000 ; 97 : 11960 -5
2	Bradley W, Doble, James R.Woodgett ＊GSK-3: tricks of the trade for a mult i - tasking kinase[ J] . J Cell Sci, 2003; 116: 1175 -86
3	段有金, 王韶颖, 三轮一智, 奥田润.五种中药对蛋白质非酶糖基化的抑制作用[ J] .中国糖尿病杂志, 1998; 6: 227-
9	4 郭啸华, 刘志红, 李恒, 黎磊石.高糖高脂饮食诱导的 2 型糖尿病大鼠模型及其肾病特点[ J] .中国糖尿病杂志, 2002; 10: 290 -4
5	李光伟, 潘孝仁, Lillioja S .检测人群胰岛素敏感性的一项新指数[ J] .中华内科杂志, 1993 ; 32: 656-60
6	Valverde AM, Burks DJ, Fabregat I, Fisher TL, Carretero J, White MF, Benito M . Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes[ J] . Diabetes, 2003; 9 : 2239-48
7	Jorgen FP, Wojtazsewski, Pernille N, Bente K, Erik A.Richter. Regulation of Gly cogen Synthasa Kinase-3 in Human Skeletal Muscle[ J] . Diabetes, 2001 ; 50: 265-9
8	Myers MG. IRS-1activates phosphatidylinositol 3'-kinase by as- sociating with src homology 1 domains of p85[ J] . Proc Natl Acad Sci USA, 1992 ; 89: 10350-4
9	Liberman Z, Eldar-Finkelman H . Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase-3 attenuatesin- sulin signaling[ J] . J Biol Chem, 2005; 280: 4422 -8
10	Eldar-Finkelman H . Phosphorylation of insulin receptor substrate
1	by glycogen synthase kinase 3 impairs insulin action[ J] . Proc Natl Acad Sci USA, 94; 9660-4
11	Lochhead PA, Coghlan M, Rice SQJ, Sutherland C . Inhibition of GSK-3 selectively reduces glucose-6-phosphate and phos- phoenolpyruvate carboxykinase gene expression[ J] .Diabetes, 2001 ; 50: 937-46
12	朱庆磊, 吕欣然.葛根素的药理学和临床应用研究进展 [ J] .中草药, 1997; 28 : 691-6
13	张妍, 毕会民, 甘佩珍.葛根素对胰岛素抵抗大鼠骨骼肌中蛋白激酶 B 表达影响[ J] .中国药理学通报, 2004; 20: 307 -10
14	李娟娟, 毕会民.葛根素对胰岛素抵抗大鼠脂肪细胞葡萄糖转运蛋白 4 的影响[ J] .中国临床药理学与治疗学, 2004 ; 9: 885-8

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[4]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[5]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[6]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[7]	CHEN Yining, XIAO Yun, HAN Xiaoyu, HUANG Lulu, MA Jingsheng, XIONG Hanbin, FU Yu, WANG Baolin, GUO Xiaohui, ZHONG Lin, AO Jiangen, HE Jiake. Diagnosis and individualized drug therapy for the rejection with hyperglycemia after liver Transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 550-555.
[8]	SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
[9]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[10]	WEI Feng, HE Yang, FAN Zhiqiang, LIU Shikun, OUYANG Linqi. Inhibitory effect of flufenidone on TGF-β1/Smads pathway in hepatocytes of rats with diethylnitrosamine (DEN)-induced liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 739-746.
[11]	LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying. Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
[12]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[13]	XING Bomin, GUO Na, NING Haihui, DING Xinyun, MA Yuqing. Effects of Rho kinase inhibitors on septic liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 544-550.
[14]	QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
[15]	ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.